 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
1 News |  |
| «12345678910111213...1314» |
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Pfizer
New P2 trial: A prospective, multicenter, single arm clinical study evaluating the effectiveness and safety of bladder preservation therapy with Disitamab Vedotin combined with toripalimab and pelvic lymph node dissection in cT2-4aN0M0 bladder urothelial carcinoma patients with HER2 expression ? 2+ after maximum transurethral bladder tumor resection (EUDRACT) - Jul 15, 2024
P2, N=63, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
New P2 trial: A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination with Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients with High Risk Factors for Recurrence (EUDRACT) - Jul 15, 2024
P2, N=60, Not yet recruiting, Sponsor: Peking University First Hospital; Peking University First Hospital
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
New P2 trial: The outcomes of disitamab vedotin combining with BCG intravesical instillation in HER2 overexpression high-risk non-muscle invasive bladder cancer (EUDRACT) - Jul 15, 2024
P2, N=70, Not yet recruiting, Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
- | Tai'ai (telitacicept) / Rongchang Pharma
New P1/2 trial: A clinical study of Telitacicept combined with traditional regimens in refractory lupus nephritis in children (EUDRACT) - Jul 15, 2024
P1/2, N=34, Recruiting, Sponsor: Children's Hospital of Fudan University; Children's Hospital of Fudan University
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Enrollment open: Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jul 11, 2024
P2, N=20, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting
- || Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Clinical, Review, Journal, Metastases: Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review. (Pubmed Central) - Jul 11, 2024
In particular, RC48 has low side effects and can be well tolerated by elderly patients after dose adjustment, providing them with treatment opportunities. It needs to be further discussed in the future research.
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Journal, IO biomarker: Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression. (Pubmed Central) - Jul 11, 2024
Disitamab vedotin combined with immunotherapy demonstrated a long-term clinical benefit in advanced Her-2-positive EMPD. For rare solid tumors with Her-2 overexpression, disitamab vedotin combined with immunotherapy might offer a viable therapeutic choice.
- || Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Enrollment open: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 (clinicaltrials.gov) - Jul 11, 2024
P1/2, N=24, Recruiting, Sponsor: RemeGen Co., Ltd.
For rare solid tumors with Her-2 overexpression, disitamab vedotin combined with immunotherapy might offer a viable therapeutic choice. Not yet recruiting --> Recruiting
- | R-Spondin1 (NU-206) / ARCA Biopharma
Journal, Surgery: Enhancing precision in colorectal cancer surgery: development of an LGR5-targeting RSPO1 peptide mimetic as a contrast agent for intraoperative fluorescence molecular imaging. (Pubmed Central) - Jul 10, 2024
Herein, we report on the synthesis and validation of a 37 amino acid RSPO1-mimetic peptide, termed RC18, that was specifically designed to access the R-spondin binding site of LGR5 to potentially be used for interoperative imaging of CRC-PM. The receptor-binding capabilities of the RC18 indicate that direct interactions with LGR5 neither significantly increased LGR5 signaling nor blocked RSPO1 binding and signal transduction, suggesting that the RSPO1-mimetic is functionally inert, making it an attractive contrast agent for intraoperative CRC-PM imaging.
- | Aidixi (disitamab vedotin) / Pfizer, Kaitanni (cadonilimab) / Akesobio
New P2 trial, Combination therapy, Metastases: RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer (clinicaltrials.gov) - Jul 8, 2024
P2, N=20, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- || Tai'ai (telitacicept) / Rongchang Pharma
P2 data, Journal: A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. (Pubmed Central) - Jul 6, 2024
Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase 3 clinical trial.
- || Tyvyt (sintilimab) / Eli Lilly, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Aidixi (disitamab vedotin) / Pfizer
New P2 trial: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer (clinicaltrials.gov) - Jul 4, 2024
P2, N=28, Recruiting, Sponsor: Wuhan Union Hospital, China
- || Filspari (sparsentan) / Travere Therap, Tai'ai (telitacicept) / Rongchang Pharma, Tarpeyo (budesonide) / Calliditas, Stada
Review, Journal: Current understanding and new insights in the treatment of IgA nephropathy. (Pubmed Central) - Jul 3, 2024
Finally, the recent large randomized controlled trials focusing on these novel targets have been summarized, among which Nefecon and Sparsentan have received approval and Telitacicept have been used off-label for IgAN. In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms.
- | Tai'ai (telitacicept) / Rongchang Pharma
Enrollment open: Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=176, Recruiting, Sponsor: RenJi Hospital
In the future, emerging treatment approaches for IgAN is likely to evolve, which will signify a shift in the management of the IgAN from traditional immunosuppressive approaches to an era of targeted treatment based on the understanding of the pathogenic mechanisms. Not yet recruiting --> Recruiting
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Review, Journal: Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review. (Pubmed Central) - Jul 2, 2024
The data suggest a promising role for DS8201 in managing advanced stages of HER2-amplified metastatic breast cancer, especially in cases that demonstrate progression after initial HER2-directed therapies using ADCs. Furthermore, its combination with anti-PD-1 agents enhances therapeutic efficacy by augmenting the anti-tumoral immune response.
- | Sulanda (surufatinib) / Hutchmed
Journal, Metastases: Case report: Remarkable response to later-line surufatinib in an adult patient with liver metastatic of pancreatoblastoma. (Pubmed Central) - Jul 1, 2024
Furthermore, its combination with anti-PD-1 agents enhances therapeutic efficacy by augmenting the anti-tumoral immune response. Surufatinib has demonstrated a progression-free survival (PFS) of no less than 14
- Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
Observational data, Retrospective data, Journal: Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study. (Pubmed Central) - Jul 1, 2024
The achievement of LLDAS is attainable in the management of SLE patients undergoing treatment with telitacicept or belimumab in real-life clinical practice. Baseline lymphocyte counts, serum albumin levels, hematological involvement and the use of telitacicept serve as robust predictors for early-achieved LLDAS, helping to identify patients who are likely to benefit on the treatment.
- || Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
P1 data, Journal, Metastases: Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study. (Pubmed Central) - Jun 28, 2024
Baseline lymphocyte counts, serum albumin levels, hematological involvement and the use of telitacicept serve as robust predictors for early-achieved LLDAS, helping to identify patients who are likely to benefit on the treatment. DV demonstrated promising efficacy in HER2-overexpression and HER2-low ABC, with a favorable safety profile at 2.0 mg/kg Q2W.
- ||||| Aidixi (disitamab vedotin) / Pfizer
Enrollment change, Combination therapy, Metastases: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer (clinicaltrials.gov) - Jun 23, 2024
P2/3, N=130, Recruiting, Sponsor: RemeGen Co., Ltd.
DV demonstrated promising efficacy in HER2-overexpression and HER2-low ABC, with a favorable safety profile at 2.0 mg/kg Q2W. N=60 --> 130
- | Tai'ai (telitacicept) / Rongchang Pharma
Journal: Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement. (Pubmed Central) - Jun 18, 2024
Importantly, the observed adverse events were manageable and controllable. Key Points
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Journal: Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy. (Pubmed Central) - Jun 17, 2024
Key Points No abstract available
- | Tai'ai (telitacicept) / Rongchang Pharma
New trial, Real-world evidence, Compliance, Real-world: Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jun 13, 2024
P=N/A, N=139, Recruiting, Sponsor: Tongji Hospital
- |||||||| Tai'ai (telitacicept) / Rongchang Pharma
New P3 trial: A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG) (clinicaltrials.gov) - Jun 12, 2024
P3, N=180, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
New P3 trial: A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) (clinicaltrials.gov) - Jun 12, 2024
P3, N=350, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Journal, Combination therapy, Checkpoint inhibition, Real-world evidence, Real-world: Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study. (Pubmed Central) - Jun 6, 2024
The combination of RC48-ADC and PD-1 inhibitors proves to be a viable and safe option for bladder-sparing therapy, particularly for T2-stage MIBC patients who are ineligible for surgery and chemotherapy. This approach offers a promising new direction for bladder preservation or neoadjuvant therapy in MIBC patients.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Eficacy of disitamab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and their combinations in HER2-positive breast cancer and gastric cancer: A preclinical study with mice models (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_705;
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. (Pubmed Central) - May 23, 2024
Despite the great promise of these novel drugs, robust predictive biomarkers are needed to determine the patients who would maximally benefit. This review surveys the rationale and current state of the evidence for these new drugs and describes future directions actively being explored.
- ||| Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Phase classification, Enrollment change: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - May 23, 2024
P2, N=40, Recruiting, Sponsor: RemeGen Co., Ltd.
This review surveys the rationale and current state of the evidence for these new drugs and describes future directions actively being explored. Phase classification: P1 --> P2 | N=60 --> 40
- ||| Aidixi (disitamab vedotin) / Pfizer
Enrollment open: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer (clinicaltrials.gov) - May 23, 2024
P2, N=79, Recruiting, Sponsor: RemeGen Co., Ltd.
Phase classification: P1 --> P2 | N=60 --> 40 Not yet recruiting --> Recruiting
- | Tai'ai (telitacicept) / Rongchang Pharma
Journal: Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy. (Pubmed Central) - May 20, 2024
In turn, IgG-IgA or poly-IgA immune complexes showed a dose-dependent effect, consistent with proteinuria reduction during telitacicept treatment. Telitacicept lowered both circulating Gd-IgA1 and IgA-containing immune complexes, whereas IgA immune complex levels were more consistent with decreased proteinuria.
- | Tai'ai (telitacicept) / Rongchang Pharma
Retrospective data, Journal: Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. (Pubmed Central) - May 16, 2024
The treatment was well tolerated, with no severe adverse events such as allergy or infection reported. Our exploratory investigation suggests that telitacicept is a feasible and well-tolerated add-on therapy for refractory GMG, offering valuable clinical evidence for this novel treatment option.
- | Tai'ai (telitacicept) / Rongchang Pharma
New trial: Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients (clinicaltrials.gov) - May 1, 2024
P=N/A, N=176, Not yet recruiting, Sponsor: RenJi Hospital
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Review, Journal: Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions. (Pubmed Central) - Apr 30, 2024
This review focuses on three approved anti-HER2 ADCs (T-DM1, DS-8201a, and RC48) and reviews ongoing clinical trials and failed trials based on anti-HER2 ADCs. Finally, we address the notable challenges linked to ADC development and underscore potential future avenues for tackling these hurdles.
- ||| Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Enrollment open, Metastases: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Apr 30, 2024
P1, N=60, Recruiting, Sponsor: RemeGen Co., Ltd.
Finally, we address the notable challenges linked to ADC development and underscore potential future avenues for tackling these hurdles. Not yet recruiting --> Recruiting
- |||| Aidixi (disitamab vedotin) / Pfizer
New P2 trial: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer (clinicaltrials.gov) - Apr 28, 2024
P2, N=79, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- | New P2 trial, Metastases: RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer (clinicaltrials.gov) - Apr 25, 2024
P2, N=32, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer, Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma (clinicaltrials.gov) - Apr 25, 2024
P2, N=28, Recruiting, Sponsor: Zhejiang Cancer Hospital
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6777;
The combination of RC48 with other targeted therapy might be a potential treatment option. Fresh prior chemotherapy with anti-microtubule drugs does not seem to affect the efficacy of RC48 while further studies with larger sample size are needed.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer, Kaitanni (cadonilimab) / Akesobio
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6496;
P2
Preliminary results showed that the combination have promising efficacy in first-line treatment of la/mUC and a manageable safety profile, it may potentially provide a new option for la/mUC treatment, especially for those who cannot tolerate cisplatin-based chemotherapy. Clinical trial information: NCT06178601.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6209;
Clinical trial information: NCT06178601. The novel HER2-targeted ADC, RC48, demonstrated promising preliminary antitumor activity in patients with HER2-expressing ABC, patient with brain metastases could also benefit, with tolerable toxicities.
- Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6163;
Future studies should focus on bringing ADCs into earlier lines of therapy in this population. Anti-tumor activity of ADCs presented as overall % (95% CI).
- Tevimbra (tislelizumab-jsgr) / BeiGene, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6099;
The novel neoadjuvant combination of RC48-ADC and tislelizumab showed promising down stage efficacy in patients with HER2 positive locally advanced MIBC and the toxicities were manageable, which would be verified by the final analysis. Clinical trial information: ChiECRCT20210564.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer, Kaitanni (cadonilimab) / Akesobio
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6076;
P2
And neoadjuvant RC48-ADC combined with AK104 showed promising anti-tumor activity with high pCR rate and well tolerance in MIBC pts. More specific pathological assessment results and long-term survival data post adjuvant therapy are worth anticipating.
- BAT8007 - Bio / Thera Solutions
A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6067;
P1
BAT8007 was well-tolerated with manageable toxicity and demonstrated preliminary antitumor activity in urothelial carcinoma and NSCLC. Clinical trial information: NCT05879627.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6059;
Clinical trial information: NCT05879627. HER2 over-expression significantly influences the tumor immunity of BC and the HER2-directed ADC RC48 has demonstrated promising efficacy as adjuvant therapy in patients with HR-NMIBC according to RFS.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6041;
Background: Neoadjuvant cisplatin-based chemotherapy remains the standard systemic therapy for cisplatin-eligible patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The combination of DV and Toripalimab as neoadjuvant therapy demonstrated notable efficacy and a manageable safety profile in patients with HER2-expressing MIBC followed by either selective bladder preservation or RC.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6027;
The first-line regimen of DV plus PD-1 inhibitor for patients with advanced UC was more effective and safer than the regimen without DV. The pathway of cytoplasmic translocation and the function of ribosome may be highly correlated to the effectiveness of the regimen of ADC plus ICI.
- AiRuiKa (camrelizumab) / HLB Bio Group, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5355;
The preliminary findings suggest that the neoadjuvant combination of RC48, camrelizumab and S-1 presents a promising and safe treatment option for locally advanced resectable GC/GEJ adenocarcinoma with HER2 overexpression. Clinical trial information: ChiCTR2300075446.
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Clinical significance of HER2 expression between primary tumors and metastatic lymph nodes in patients with extramammary Paget's disease. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4977;
However, there was some heterogeneity in HER2 expression between paired primary and corresponding metastatic LNs. The expression status of HER2 should be evaluated in both primary tumors and corresponding lymph node metastases.
- Fruzaqla (fruquintinib) / Takeda, Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4683;
P4
RC48 combined with fruquintinib has shown promising efficacy and a manageable safety profile for HER2-expressing or -amplified mCRC patients refractory to at least two standard treatment failures. Clinical trial information: NCT05661357.